The HCPLive gastroesophageal reflux disease page is a comprehensive resource for clinical news and insights on GERD. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for reflux disease, and more.
December 7th 2023
The NDA submission was supported by positive data from the phase 3 PHALCON-NERD-301 study and has been assigned a standard 10-month review with a PDUFA target action date of July 19, 2024.
Popular OTC Acid Reflux Medicines May Carry Substantial Negative Side Effects, Studies Show
Atop already surprising studies that linked their daily use with increased risk of kidney failure, new data has emerged that shows they may also contribute to weakening of the bones.
Newly Approved GERD Drug Melts in Your Mouth
The US Food and Drug Administration (FDA) has approved dexlansoprazole (Dexilant SoluTab/Takeda Pharmaceuticals), a new formulation for the treatment of heartburn-associated gastroesophageal reflux disease (GERD) in adults age 18 and older.